Navigation Links
ADHD Drug Delays Puberty in Male Monkeys, Study Finds
Date:9/19/2011

By Maureen Salamon
HealthDay Reporter

MONDAY, Sept. 19 (HealthDay News) -- The widely used attention-deficit/hyperactivity disorder (ADHD) medication methylphenidate -- best known as Ritalin -- appears to be tied to delayed puberty in male monkeys.

But, researchers cautioned that the finding needs to be replicated before parents should concern themselves about similar effects in boys.

Male primates given methylphenidate over a 40-month span experienced "impaired testicular descent" and smaller-sized testicles, as well as lower testosterone levels, all of which resolved over the course of the study.

"To our knowledge, it's the first observation in primates to suggest an alteration in testicular function," said study author Dr. Donald Mattison, a medical officer at the National Institute of Child Health and Human Development, part of the U.S. National Institutes of Health.

"We believe they're interesting observations, but substantially more work needs to be done . . . to make sure they're repeatable," Mattison said. "It's really too early to say there are clinical implications."

The study is published in this week's online issue of the Proceedings of the National Academy of Sciences.

The most commonly diagnosed behavioral disorder in childhood, ADHD affects between 3 percent and 5 percent of school-age kids, mostly boys. Ritalin and other forms of methylphenidate have long been the most widely used drugs to treat ADHD, which involves issues of inattentiveness, overactivity and impulsivity. Other brand name versions of methylphenidate include Concerta, Metadate and Methylin.

According to Mattison, the young rhesus monkeys in the study were given either a low dose or high dose of methylphenidate, with the low dose designed to match typical blood levels of the drug observed in human ADHD patients. The high dose was intended to produce blood levels five to 10 times higher than used in people, he said.

"Testicular descent," part of the male maturation process, was postponed "significantly" in monkeys given the high (but not lower) dose of methylphenidate, the study found, while lowered testicular volume and blood testosterone levels were noted in monkeys given either the low- or high-dose regimens.

The effects on testicular function were a complete surprise, Mattison noted, since the study was designed to evaluate other types of potential toxicity from methylphenidate, including possible DNA damage.

"I think the results are more to keep in mind, and we haven't made any recommendations for clinical practice," he said. "But we encourage clinicians and scientists to think about puberty as a potential endpoint that might be affected. So we're pretty cautious at this point."

Dr. Spyros Mezitis, an endocrinologist at Lenox Hill Hospital in New York, said hormonal systems are very similar in primates and humans, but he has not observed any testosterone-related symptoms in patients taking methylphenidate.

"This is a standalone study . . . so we need more studies to understand what's happening here," Mezitis said. "In the endocrine community, when it comes to the use of Ritalin, we're not really considering testosterone levels, but maybe we should now."

A spokesperson for Novartis Pharmaceuticals Corp., which manufactures Ritalin, said it was important to note that the study was conducted in monkeys and showed the impact of methylphenidate on puberty was not permanent.

"We have specifically examined our post-marketing data for reports of delayed sexual maturation," spokesman Michael Billings said. "From the data available, no association between the use of our methylphenidate products and delays in sexual maturation has been been established."

More information

There's more on ADHD at the U.S. National Library of Medicine.

SOURCES: Donald Mattison, M.D., medical officer, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Md.; Dr. Spyros Mezitis, endocrinologist, Lenox Hill Hospital, New York City; Michael Billings, spokesperson, Novartis Pharmaceuticals Corp., East Hanover, N.J.; Sept. 19-23, 2011, Proceedings of the National Academy of Sciences


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. One-Third of Severe Heart Attack Patients Have Treatment Delays
2. Many Pediatricians Arent Testing Tots for Developmental Delays
3. Hospital Delays Tied to Racial Divide in Heart Attack Care
4. Delays in Hospital Transfers for Heart Attack Patients May Raise Death Risk
5. Language Delays Seen in Kids in Institutions Beyond Age 2
6. Antifungal drug delays need for chemo in advanced prostate cancer
7. FDA Panel Delays Action on Dyes Used in Foods
8. Outcomes improved by longer delays between heart attacks and elective surgeries
9. Blood Pressure Drug Delays Kidney Disease in Diabetics
10. Heart Patients With Depression Often Find ER Delays
11. Delivery Even a Bit Early May Mean Developmental Delays
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
ADHD Drug Delays Puberty in Male Monkeys, Study Finds
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the ... Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , “We ... new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice ...
(Date:6/25/2016)... ... , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department ... in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at ... Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 ...
(Date:6/24/2016)... ... , ... Those who have experienced traumatic events may suffer from a complex ... as drug or alcohol abuse, as a coping mechanism. To avoid this pain and ... a traumatic event. , Trauma sufferers tend to feel a range of emotions, from ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension ... that it will receive two significant new grants to support its work to ... its 25th anniversary by recognizing patients, medical professionals and scientists for their work ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is ... Road To Recovery® program to drive cancer patients to and from their cancer treatments. ... the highest quality of life and ongoing independence. Getting to and from medical ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Market - Forecast to 2022" report to their offering. ... method for the patients with kidney failure, it replaces the ... from the patient,s blood and thus the treatment helps to ... chloride in balance. Increasing number of ESRD ...
Breaking Medicine Technology: